Last Updated: May 10, 2026

Patent: 10,034,948


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,034,948
Title:Low molecular weight polyethylene glycol drug conjugates having improved drug biological activity
Abstract:Provided are polyethylene glycol drug conjugates of general formula (I), (II) or (III) and pharmaceutical compositions and a use thereof. The conjugates are formed by combining low molecular weight polyethylene glycol with 2-4 drug molecules. The conjugates can interact with receptor dimers or polymers, thereby improving the in vivo distribution of the drug, changing the oil and water distribution coefficient, enhancing the pharmacological activity, reducing the blood-brain barrier permeability of the drug, and improving the bioavailability of the drug.
Inventor(s):Lihua Xu, Xuan Zhao, Zewang Feng, Jinliang Wang, Zhen'guo WANG
Assignee: Jenkem Technology Co Ltd Tianjin Branch , Jenkem Technology Co Ltd
Application Number:US15/700,057
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 10,034,948: Claims and Competitive Patent Landscape

What does US Patent 10,034,948 claim?

US 10,034,948 is a US utility patent (granted July 31, 2018) with a claims set that must be interpreted through: (1) the independent claim limitations, (2) the claim dependencies, and (3) how the specification uses defined terms and embodiments. Without the claim text, priority data, and publication family members, a complete claim-by-claim legal and technical analysis cannot be produced, and any attempt would risk material inaccuracies.

No claims/embodiments text, priority chain, or publication numbers for this patent are included in the request context. Under the operating constraints, an incomplete or speculative analysis is not permitted.

What is the patent landscape around US 10,034,948 in the US?

A landscape analysis requires at least: (1) identification of the patent family and earliest priority, (2) capturing forward citations and related assignees, (3) mapping claim scope overlap against contemporaneous US applications and grants, and (4) noting whether key references are publication-family insiders versus outside prior art.

No such bibliographic or citation data is present in the prompt context. Under the operating constraints, a complete and accurate landscape cannot be produced.

What are the critical claim-scope levers that determine infringement risk?

For a comprehensive assessment, the analysis must include the precise claim limitations (for example: composition vs method vs device; active agent scope; formulation constraints; dosage forms; parameter ranges; markers; manufacturing steps; apparatus structure; and performance metrics). The infringement analysis then hinges on:

  • Claim breadth drivers (open vs closed transitions, generic vs species language, structural vs functional limitations, and whether ranges are literal or result-driven)
  • “Narrowing” dependencies that transform independent scope
  • Means-plus-function or step-plus-function language that can narrow interpretation
  • Use of defined terms (from the specification) that can convert apparent breadth into constrained embodiments

Because the claim text is not provided, these levers cannot be assessed for US 10,034,948 without introducing error.

What prior art is most likely to matter, and how can it map to claim elements?

A critical prior art map must be anchored to:

  • The patent’s effective filing date (priority and US filing)
  • The jurisdictional cutoffs for patentability (pre-AIA vs AIA; 35 USC 102/103 frameworks)
  • The patent family’s earliest priority and whether it is later or earlier than key references
  • The exact claim elements that correspond to the prior art

Without filing date and claim elements, any mapping would be incomplete.

How should competitors’ US filings be screened against this patent’s likely scope?

A proper competitor screen also requires known scope. Standard screening uses:

  • Overlapping independent claims in peer patents (same technology class and claim structure)
  • Citation-network neighbors (both backward and forward citations)
  • Continuations/divisionals that indicate contested scope
  • Assignee and inventor continuity in the field
  • Family members that broaden or narrow the same core invention

No technology-class or claim-scope anchor is available from the prompt context.

What does the existing citation and family structure imply about enforceability?

Enforceability analysis depends on:

  • Claim construction risk (ambiguity, internal inconsistencies)
  • Prosecution history estoppel triggers
  • Whether key dependent claims were added late
  • Whether the patent survived prior art rejections on similar references
  • Whether the claim set contains multiple alternative routes to infringement (which can reduce design-around efficacy)

All of these require file history and claim text. None is available in the prompt context.

Key Takeaways

No complete or accurate claim analysis or US patent landscape assessment for US 10,034,948 can be provided from the information in the request. A compliant, non-speculative review requires the patent’s claim text, bibliographic details, family members, and citation data.

FAQs

1) Can you summarize the independent claims of US 10,034,948?
Not with the information provided. Independent claim limitations must be quoted or reproduced from the patent record to avoid inaccuracies.

2) Which prior art references most likely challenge US 10,034,948?
A defensible answer requires the patent’s effective filing date and the exact claim elements to map 35 USC 102/103 challenges to specific references.

3) What design-arounds are most plausible for competitors?
Design-around identification is contingent on the claim scope and dependency structure, which are not present in the prompt context.

4) What is the patent’s likely position in the citation network?
Determining citation position requires forward and backward citations from the US record.

5) Who are the relevant competitors and assignees in the same claim space?
Competitor identification requires assignee/inventor mapping from the relevant US publications and grants, which is not provided.


References

[1] Not available: the prompt provides no bibliographic or citation source for US Patent 10,034,948.

More… ↓

⤷  Start Trial

Details for Patent 10,034,948

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen Inc. VECTIBIX panitumumab Injection 125147 September 27, 2006 ⤷  Start Trial 2037-09-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,034,948

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2014190763 ⤷  Start Trial
United States of America 9789198 ⤷  Start Trial
United States of America 2018177884 ⤷  Start Trial
United States of America 2018021443 ⤷  Start Trial
United States of America 2018021442 ⤷  Start Trial
United States of America 2017368191 ⤷  Start Trial
United States of America 2016082117 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.